Commercial

Disappointing sales prompt AstraZeneca to pull out leukemia drug Lumoxiti from U.S. market

In a letter shared with healthcare providers, AstraZeneca has announced that it will be pulling its leukemia antibody-drug conjugate Lumoxiti (moxetumomab pasudotox-tdfk)...

Sanofi’s Venture Capital units to receive over $750 million in investment to boost firm’s investment capabilities 

After a successful last year in which Sanofi Ventures made its second-highest number of deals, 10 rounds of backing that amount to...

Spiral Therapeutics completes $8.25M financing for phase 2 trial of hearing medication

Spiral Therapeutics has recently closed an $8.25 million financing round for the phase 2 research and development of SPT-2101, which is the...

Alphabet’s health subsidiary Verily cuts staff by 15% in a bid to strategize and reorganize

In an email shared with Verily employees recently, the company CEO Stephen Gillett announced that they will be laying off 15% of...

Fate, Century, and TCR2 Therapeutics make major cuts to staff and research

Fate, Century, and TCR2 Therapeutics have planned to reorganize in the new year signaling longer plans for cell therapy development for cancer.

Amazon Inches Closer to Acquiring One Medical

Amazon has moved closer to finalizing its $3.9 billion acquisition of One Medical after receiving approval from Oregon’s health agency.

Novartis pays $245 million to close Exforge lawsuit

Novartis has made the decision to resolve all legal pay-for-delay disputes by making final settlements. Novartis will pay a total of $245...

In latest developments, HistoSonics sees greater funding and board addition

HistoSonics, a private medical device company, is in the process of developing a non-invasive platform with the aid of histotripsy to prepare...

Latest news

FDA and CDC exploring unlikely relation between COVID-19 vaccine and stroke

The FDA and CDC have brought out new revelations that the revised COVID-19 injection from Pfizer Inc...

Disappointing sales prompt AstraZeneca to pull out leukemia drug Lumoxiti from U.S. market

In a letter shared with healthcare providers, AstraZeneca has announced that it will be pulling its leukemia...

Sanofi’s Venture Capital units to receive over $750 million in investment to boost firm’s investment capabilities 

After a successful last year in which Sanofi Ventures made its second-highest number of deals, 10 rounds...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you

Adragos acquires Sanofi facility in Japan in bid to expand production network

Adragos Pharma is a German pharmaceutical Contract...

FDA Pushes Back Lynparza Decision to March

The U.S. Food and Drug Administration (FDA)...